Copyright 1999 American Medical Association.
All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999
To the Editor: The increasing market
of smoking cessation pharmacotherapies underscores the great need for
these prescription and over-the-counter products for this worldwide
health problem. It is important to discuss another area of
pharmacotherapy for smoking cessation that was not discussed in the
article by Dr Hughes and colleagues.1
Rose and colleagues2 have demonstrated the therapeutic
utility of combining the nicotine antagonist mecamylamine with nicotine
for the treatment of smoking cessation. These investigators
demonstrated that mecamylamine given orally with nicotine patches
significantly prolonged the duration of continuous smoking
abstinence.2 Furthermore, this combination reduced ad-lib
smoking, smoking satisfaction, and cigarette craving. These studies
have promoted the development of the mecamylamine nicotine patch
currently in phase 3 clinical trials. However, it is now possible to
use oral mecamylamine and nicotine patches as was done in the study by
Rose et al.
Goldman J, Shytle RD, Sanberg PR. Adding Behavioral Therapy to Medication for Smoking Cessation. JAMA. 1999;281(21):1983–1985. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: